FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a protein containing the first polypeptide, which binds programmed death ligand 1 (hereinafter – PD-L1) human protein and which is capable of binding TGFβ and the second polypeptide containing at least variable domain of an antibody light chain, which binds PD-L1, where the heavy chain of the first polypeptide and the light chain of the second polypeptide, when combining, form an antigen-binding site, which binds PD-L1, as well as to a nucleic acid molecule encoding the above-mentioned protein, to a selected cell containing the nucleic acid molecule for the use when producing the protein, to a method for producing the protein, to a pharmaceutical composition for the treatment of tumor or cancer, to use of the protein when producing a drug for inhibiting tumor growth in a patient or for treating cancer in a patient, to a method for inhibiting tumor growth in a patient and to a method for treating cancer in a patient.
EFFECT: group of inventions is aimed at inhibiting tumor growth and treating cancer in a patient.
17 cl, 18 dwg, 1 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
